Asean as a whole has reported more than 15.9 million COVID-19 cases. Of this, more than 800,000 are active cases as of January 21.
The coronavirus COVID-19 is affecting 219 countries and territories around the world and 2 international conveyances.
Administrering of 3rd booster dose against COVID-19 in Cambodia finally takes off along with 4th dose
The 3rd booster dose has now been administered to 5,073,265 people, including 2,587,619 females while the fourth dose which started on January 14 has seen a total of 204,730 getting it as of January 20.
To date, since vaccination first started on February 10, 2021, a total of 14,326,513 people have received their first dose of the vaccine while 13,728,089 have received their second dose to complete their two course vaccine programme.
Latest official COVID-19 data
Source: Indonesian government
Last Update: Jan 20, 2022
Jakarta braces for impending ‘battle’ with Omicron A woman receives a booster dose of the Pfizer COVID-19 vaccine in Jakarta on Jan. 12, 2022. (AFP/Adek Berry) Share Nina A. Loasana (The Jakarta Post) PREMIUM Jakarta ● Tue, January 18, 2022 Jakartans are being called upon to be more vigilant and consider once again the possibility of working from home, after authorities flagged the city as the “first battleground” in the fight against the Omicron COVID-19 strain, amid worrying predictions of a third infection wave in the coming weeks.
This article was published in thejakartapost.com with the title “Jakarta braces for impending ‘battle’ with Omicron”.
Lao factory producing Molacovir for treatment of Covid patients
State Enterprise Pharmaceutical Factory No. 3 in Vientiane is manufacturing a revolutionary new drug named Molacovir for use in the early stages of Covid-19.
The drug is administered orally and under Lao copyright is known as Molacovir.
The new drug formula was first used in the treatment of influenza and was developed by scientists at Emory University in the United States.
The US Food and Drug Administration (FDA) has approved molnupiravir for use in the early treatment of Covid-19 patients, raising confidence in the future reduction of the high mortality rate from the virus